Penumbra (PEN) Shares Outstanding (Weighted Average) (2014 - 2026)
Penumbra (PEN) reported Shares Outstanding (Weighted Average) of $39.3 million for Q1 2026, up 1.85% year-over-year from $38.6 million in Q1 2025, and up 0.92% quarter-over-quarter from $38.9 million in Q4 2025.
Penumbra (PEN) Shares Outstanding (Weighted Average) (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $39.3 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $39.3 million, up 1.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.3 million (up 1.85% YoY), and the FY2025 annual result was $38.9 million, up 0.74% from the prior year.
- Shares Outstanding (Weighted Average) improved to $39.3 million in Q1 2026 per PEN's latest filing, from $38.9 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $39.3 million in Q1 2026 and troughed at $37.6 million in Q1 2022.
- A 5-year average of $38.5 million and a median of $38.6 million in 2025 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) grew 3.55% in 2022, then fell 0.4% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $37.8 million in 2022, then gained by 1.48% to $38.4 million in 2023, then grew by 0.61% to $38.6 million in 2024, then climbed by 0.74% to $38.9 million in 2025, then advanced by 0.92% to $39.3 million in 2026.
- Business Quant data shows PEN's Shares Outstanding (Weighted Average) at $39.3 million in Q1 2026, $38.9 million in Q4 2025, and $39.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.74 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 382.90 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.28 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.48 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 579.20 Mn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 456.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 385.10 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 98.20 Mn |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | 39.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.28 Mn |
| Dec 31, 2025 | 38.92 Mn |
| Sep 30, 2025 | 39.08 Mn |
| Jun 30, 2025 | 38.83 Mn |
| Mar 31, 2025 | 38.56 Mn |
| Dec 31, 2024 | 38.63 Mn |
| Sep 30, 2024 | 38.61 Mn |
| Jun 30, 2024 | 38.79 Mn |
| Mar 31, 2024 | 38.72 Mn |
| Dec 31, 2023 | 38.40 Mn |
| Sep 30, 2023 | 38.32 Mn |
| Jun 30, 2023 | 38.25 Mn |
| Mar 31, 2023 | 38.19 Mn |
| Dec 31, 2022 | 37.84 Mn |
| Sep 30, 2022 | 37.92 Mn |
| Jun 30, 2022 | 37.77 Mn |
| Mar 31, 2022 | 37.65 Mn |
| Dec 31, 2021 | 36.76 Mn |
| Sep 30, 2021 | 36.62 Mn |
| Jun 30, 2021 | 36.52 Mn |